BACKGROUND: Rasburicase, a recombinant urate oxidase, is used to rapidly metabolize uric acid in patients with hyperuricaemia. Rasburicase is an immunogenic therapeutic protein, which has been shown to elicit antibody response in 64 % of healthy volunteers within 1-6 weeks after the initial course, with persistent antibodies for over 1 year. Drug labelling indicates that anaphylaxis rarely occurs (in <1 % of patients) after a single course of therapy with rasburicase, but there are no data available on the incidence of anaphylaxis in patients receiving a subsequent rasburicase course. OBJECTIVE: The objective of this study was to determine the incidence of anaphylaxis after multiple treatment courses of rasburicase. METHODS: A retrospective chart review was performed on 97 consecutively treated patients who received repeated courses of rasburicase for hyperuricaemia. RESULTS: None of the 97 patients who were reviewed experienced anaphylaxis during the first rasburicase course; however, six patients (6.2 %) experienced anaphylaxis during a subsequent rasburicase treatment course (p = 0.03). CONCLUSION: Anaphylaxis after a second course of rasburicase appears to occur more frequently than described in the US Food and Drug Administration-approved package insert for initial treatment courses. Given the serious nature of anaphylactic events, caution is advised when administering repeated courses of rasburicase.
BACKGROUND: Rasburicase, a recombinant urate oxidase, is used to rapidly metabolize uric acid in patients with hyperuricaemia. Rasburicase is an immunogenic therapeutic protein, which has been shown to elicit antibody response in 64 % of healthy volunteers within 1-6 weeks after the initial course, with persistent antibodies for over 1 year. Drug labelling indicates that anaphylaxis rarely occurs (in <1 % of patients) after a single course of therapy with rasburicase, but there are no data available on the incidence of anaphylaxis in patients receiving a subsequent rasburicase course. OBJECTIVE: The objective of this study was to determine the incidence of anaphylaxis after multiple treatment courses of rasburicase. METHODS: A retrospective chart review was performed on 97 consecutively treated patients who received repeated courses of rasburicase for hyperuricaemia. RESULTS: None of the 97 patients who were reviewed experienced anaphylaxis during the first rasburicase course; however, six patients (6.2 %) experienced anaphylaxis during a subsequent rasburicase treatment course (p = 0.03). CONCLUSION:Anaphylaxis after a second course of rasburicase appears to occur more frequently than described in the US Food and Drug Administration-approved package insert for initial treatment courses. Given the serious nature of anaphylactic events, caution is advised when administering repeated courses of rasburicase.
Authors: Charles L Bennett; Jonathan R Nebeker; Paul R Yarnold; Cara C Tigue; David A Dorr; June M McKoy; Beatrice J Edwards; John F Hurdle; Dennis P West; Denys T Lau; Cara Angelotta; Sigmund A Weitzman; Steven M Belknap; Benjamin Djulbegovic; Martin S Tallman; Timothy M Kuzel; Al B Benson; Andrew Evens; Steven M Trifilio; D Mark Courtney; Dennis W Raisch Journal: Arch Intern Med Date: 2007-05-28
Authors: S Trifilio; L Gordon; S Singhal; M Tallman; A Evens; K Rashid; M Fishman; K Masino; J Pi; J Mehta Journal: Bone Marrow Transplant Date: 2006-06 Impact factor: 5.483
Authors: A Ahsan Ejaz; Wei Mu; Duk-Hee Kang; Carlos Roncal; Yuri Y Sautin; George Henderson; Isabelle Tabah-Fisch; Birgit Keller; Thomas M Beaver; Takahiko Nakagawa; Richard J Johnson Journal: Clin J Am Soc Nephrol Date: 2006-12-06 Impact factor: 8.237
Authors: M J Gold; P R Hiebert; H Y Park; D Stefanowicz; A Le; M R Starkey; A Deane; A C Brown; G Liu; J C Horvat; Z A Ibrahim; M B Sukkar; P M Hansbro; C Carlsten; S VanEeden; D D Sin; K M McNagny; D A Knight; J A Hirota Journal: Mucosal Immunol Date: 2015-10-28 Impact factor: 7.313
Authors: Christopher Jenkins; Jennifer H Hwang; Jeffrey B Kopp; Cheryl A Winkler; Sung Kweon Cho Journal: Front Pharmacol Date: 2022-08-23 Impact factor: 5.988